Auxenion is a German/Swiss drug discovery company that develops novel pharmaceutical assets by integrating chemistry, biology, proteomics, and bioinformatics into a single discovery engine. Built on a proprietary library of bioactive molecules and a target-agnostic, phenotypic discovery process, our core focus is targeted cancer therapy, including metabolic regulator programs, alongside a broader portfolio spanning fibrotic, metabolic, and autoimmune disorders.
Our core focus is targeted cancer therapy, led by first-in-class metabolic regulator programs. In vitro analysis has validated their impact on the metabolism of cancer cells, and in vivo data show tumor growth inhibition.
Our discovery engine is built on a proprietary library of bioactive molecules, expanded into untouched chemical space. Five global umbrella patent families protect both compound structures and applications, with thousands of molecules already filed.
Our founding team combines clinical medicine, cancer research, and chemistry, supported by scientific and business advisors with experience across oncology, translational medicine, and global pharma strategy.
Auxenion is guided by a board of advisors with decades of experience across oncology, medicine, and global pharmaceutical strategy, including former roles at Novartis, Roche, Pfizer, GSK and BMS, alongside academic affiliations with the ETH and the EPFL. This depth of expertise supports our path from discovery science to validated therapeutic assets.
